138 related articles for article (PubMed ID: 19899983)
1. Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system.
Si EC; Cheung PS; Bowman L; Hosseini K
Curr Eye Res; 2009 Jun; 34(6):485-91. PubMed ID: 19899983
[TBL] [Abstract][Full Text] [Related]
2. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits.
Amar T; Caillaud T; Elena PP
Curr Eye Res; 2008 Feb; 33(2):149-58. PubMed ID: 18293185
[TBL] [Abstract][Full Text] [Related]
3. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.
Akpek EK; Vittitow J; Verhoeven RS; Brubaker K; Amar T; Powell KD; Boyer JL; Crean C
J Ocul Pharmacol Ther; 2009 Oct; 25(5):433-9. PubMed ID: 19857105
[TBL] [Abstract][Full Text] [Related]
4. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
Stewart WC; Crean CS; Zink RC; Brubaker K; Haque RM; Hwang DG
Am J Ophthalmol; 2010 Nov; 150(5):744-751.e2. PubMed ID: 20813346
[TBL] [Abstract][Full Text] [Related]
7. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
8. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin.
Kuehne JJ; Yu AL; Holland GN; Ramaswamy A; Taban R; Mondino BJ; Yu F; Rayner SA; Giese MJ
Am J Ophthalmol; 2004 Oct; 138(4):547-53. PubMed ID: 15488779
[TBL] [Abstract][Full Text] [Related]
9. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin.
Bowman LM; Si E; Pang J; Archibald R; Friedlaender M
J Ocul Pharmacol Ther; 2009 Apr; 25(2):133-9. PubMed ID: 19284320
[TBL] [Abstract][Full Text] [Related]
10. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers.
Chiambaretta F; Garraffo R; Elena PP; Pouliquen P; Delval L; Rigal D; Dubray C; Goldschmidt P; Tabbara K; Cochereau I
Eur J Ophthalmol; 2008; 18(1):13-20. PubMed ID: 18203079
[TBL] [Abstract][Full Text] [Related]
11. Ocular levels of azithromycin.
Tabbara KF; al-Kharashi SA; al-Mansouri SM; al-Omar OM; Cooper H; el-Asrar AM; Foulds G
Arch Ophthalmol; 1998 Dec; 116(12):1625-8. PubMed ID: 9869792
[TBL] [Abstract][Full Text] [Related]
12. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
[TBL] [Abstract][Full Text] [Related]
13. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
Dorfman MS; Wagner RS; Jamison T; Bell B; Stroman DW
Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of azithromycinin rabbit lacrimal glands and conjunctiv a.
Karcioglu ZA; Ahmed WS; Raines D; El-Yazigi A
Ophthalmic Res; 1999; 31(1):47-52. PubMed ID: 9831822
[TBL] [Abstract][Full Text] [Related]
15. Propagation of error in ocular pharmacokinetic parameters estimate of azithromycin in rabbits.
You L; Qian J; Wu X; Sun X; Su M; Di B; Du Y; Mao B
J Pharm Sci; 2013 Jul; 102(7):2371-9. PubMed ID: 23649959
[TBL] [Abstract][Full Text] [Related]
16. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
17. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.
Utine CA
Clin Ophthalmol; 2011; 5():801-9. PubMed ID: 21750614
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
19. An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin.
Ness PJ; Mamalis N; Werner L; Maddula S; Davis DK; Donnenfeld ED; Olson RJ
Am J Ophthalmol; 2010 Oct; 150(4):498-504.e1. PubMed ID: 20678751
[TBL] [Abstract][Full Text] [Related]
20. Limited Azithromycin Localization to Rabbit Meibomian Glands Revealed by LC-MS-Based Bioanalysis and DESI Imaging.
Asano N; Wiseman JM; Tsuji F; Kawazu K
Biol Pharm Bull; 2017; 40(9):1586-1589. PubMed ID: 28867744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
